Lupin Ltd.

Financial

	Lupin	Dr. Reddy's Lab	Zydus Lifesciences
Operational Metrics
API Sector
US DMF Filings	156.0 .	n/a	142.0 .
Pharmaceutical Sector
Number of ANDA's Filed in USA	430.0 .	354.0 .	483.0 .
Number of ANDA's Approved By USFDA	334.0 .	275.0 .	415.0 .
Domestic Sales Growth - YoY	7.3 %	9.3 %	9.4 %
R&D as a % of Total Sales	7.7 %	8.0 %	8.1 %
Financials
5 yr Average ROE	2.19 %	14.9 %	16.96 %
5yr average Equity Multiplier	1.79	1.41	1.66
5yr Average Asset Turnover Ratio	0.72	0.77	0.65
5yr Avg Net Profit Margin	1.82 %	14.03 %	16.78 %
Price to Book	6.14	3.26	4.06
P/E	33.5	18.66	19.51
5yr Avg Cash Conversion Cycle	-70.43 Days	64.1 Days	-68.16 Days
Inventory Days	51.95 Days	75.39 Days	44.51 Days
Days Receivable	52.75 Days	99.54 Days	46.37 Days
Days Payable	155.88 Days	102.35 Days	164.0 Days
5yr Average Interest Coverage Ratio	3.96	34.06	24.75
5yr Avg ROCE	8.04 %	19.83 %	17.68 %
5yr Avg Operating Profit Margin	12.57 %	21.19 %	22.37 %
5 yr average Debt to Equity	0.34	0.12	0.3
5yr CAGR Net Profit	n/a	22.45 %	26.82 %
5yr Average Return on Assets	1.4 %	10.71 %	10.66 %
Shareholdings
Promoter Holding	46.92 %	26.64 %	74.99 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.14 %	-0.08 %	0.11 %
Change in Mutual Fund Holding (3 Yrs)	1.83 %	-1.23 %	0.81 %

Business

	Lupin	Dr. Reddy's Lab	Zydus Lifesciences
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 Proprietary Products 0 Global Generics 0 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 Wellness 0 Animal Health 0 EMB Formulations 0 India Formulations 0 US Formulations 0	Product Wise Break-Up Pharmaceutical 9.83 Generic FDF 0 NCD 0 USA 0 Developed Markets 0 Proprietary 1.93 Custom Synthesis 0 India 0 India Formulations 0 US Formulations 0 Active Pharmaceutical Ingredient (API) 0 Emerging Markets 0 EMB Formulations 0 Alliances 0 Wellness 0 Europe Formulatios 0 Advanced Markets Formulations 0 Formulations 88.24 Animal Health 0 Emerging Market 0	Product Wise Break-Up 0 Generic FDF 0 NCD 0 USA 0 Developed Markets 0 Proprietary Products 0 Custom Synthesis 0 India 0 India Formulations 29.0 US Formulations 47.0 Active Pharmaceutical Ingredient (API) 0 Emerging Markets 0 EMB Formulations 0 Alliance 1.0 Wellness 9.0 Europe Formulatios 0 Advanced Markets Formulations 0 Global Generics 0 Animal Health 0 Emerging Market 0 Others 14.0
Segment Break-Up	Segment Break-Up Pharmaceuticals 99.54 Research Services & Sale of IP`s 0 Consumer Products 0 Others 0.46	-	Segment Break-Up OTC 8.71 Pharmaceuticals 91.29 Research Services & Sale of IP`s 0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Cardiac Science 24.0 Anti - Diabetes 22.0 Respiratory Systems 14.0 Gastro Intestinal 7.0 Gynecology 6.0 Anti-Infective 6.0 Vitamins / Minerals / Nutrients 5.0 Anti-Tuberculosis 4.0 Central Nervous System (CNS) 4.0 Pain Management 3.0 Others 5.0	-	-
Location Wise Break-Up	Location Wise Break-Up USA 38.0 India 34.0 EMEA 11.0 Developed Markets 8.0 API 5.0 Japan 0 Russia 0 Others 4.0	Location Wise Break-Up Japan 0 Russia 7.99 EMEA 0 India 17.36 USA 48.56 API 0 Developed Markets 0 Others 26.09	Location Wise Break-Up Japan 0 Russia 0 EMEA 0 India 41.0 USA 44.89 API 0 Developed Markets 0 Others 14.11
Acute vs Chronic	Acute vs Chronic Acute 66.0 Chronic 34.0	-	-

Lupin Ltd.

SIGN UP FOR FREE